Neurology Research International

Neurology Research International is an open access journal of clinical and basic neurology, published by Wiley and founded in 2010 under Hindawi. It carries work on neurological disorders and on normal neurological function, from animal models through to clinical trials. The 2025 Journal Impact Factor is 2.4 and CiteScore is 4.6.《国际神经病学研究》是一本临床与基础神经病学的开放获取期刊，由 Wiley 出版，2010 年在 Hindawi 旗下创刊。刊物登载神经系统疾病与正常神经功能方面的研究，取材从动物模型一直延伸到临床试验。2025 年期刊影响因子为 2.4，CiteScore 为 4.6。

Scope

• The remit is written broadly, as every aspect of neurological disorders together with normal neurological function, and no subspecialty is fenced off from the rest of the field.刊物的取材范围写得很宽，神经系统疾病的各个方面连同正常神经功能都在其中，没有哪个亚专业被单独划出去。

• Basic laboratory work on the mechanisms of neurological disease sits here beside work done at the bedside, and the guidelines give neither side weight over the other.神经系统疾病机制的基础实验研究与床旁研究并列收录，投稿指南没有给任何一边更多分量。

• Translational studies that carry a finding from bench to patient are welcomed, as are studies that only clear the ground for that later step and claim nothing more.把发现从实验室推向患者的转化研究受欢迎，只为此后这一步清理地基而不作更多断言的研究同样在列。

• Clinical research reaches the journal alongside laboratory work, ranging from observational patient series to prospective trials run to a registered protocol.临床研究与实验室工作一起进入刊物，范围从观察性病例系列一直到按注册方案执行的前瞻性试验。

• Animal models form part of the scope, and the aims page lists them beside clinical trials as one of the study designs it receives.动物模型属于收稿范围，宗旨页把它与临床试验并列，作为接收的研究设计之一。

• Clinical trials may be submitted, and registration in a public registry that meets the ICMJE standard is required.临床试验可以投来，须已在符合 ICMJE 标准的公共平台完成注册。

• Normal neurological function is named in the scope beside disease, so work on healthy physiology and on measurement in people who are unaffected has a place of its own.正常神经功能与疾病并列写进范围，健康生理学以及对未患病人群所作的测量研究都各有一席。

• The scope is drawn by subject rather than by technique, so imaging, electrophysiology and biomarker studies all have a place.范围按主题而非技术手段划定，影像学、电生理与生物标志物研究都有一席之地。

• Systematic reviews are accepted too, and the guidelines treat them as research articles rather than as a separate type.系统综述同样接收，投稿指南把它按研究论文处理，不单列一类。

• Reviews make up the second manuscript type, and the journal lists no third category for shorter notices.综述是第二类稿件，刊物没有为短讯另列第三类。

• Case reports and short correspondence are not among the accepted types, which keeps the annual article count small and the mix of formats narrow.病例报告与短篇通讯不在收稿类型之列，年发文量因此保持在低位，体裁也收得窄。

• Coverage is not cut into sections, so a paper on epilepsy and a paper on dementia are judged against the same criteria.栏目没有把范围切开，癫痫论文与痴呆论文按同一套标准衡量。

• Every accepted article is deposited in PubMed Central, so the output reaches the public biomedical archive instead of stopping at a licence page on the publisher's site.录用的文章全部存入 PubMed Central，刊物的产出进入公共生物医学档案，不会停在出版方的授权页后面。

History

• The first volume carries the year 2010 in place of a number, and the NLM catalogue records 2010 as the title's first year of publication.创刊卷直接以 2010 年代替序号，NLM 目录把这一年记为首个出版年。

• Hindawi brought the new title out from New York, and the imprint held by the NLM catalogue still preserves that origin for the early volumes.新刊由 Hindawi 在纽约出版，NLM 目录的出版项至今为早期各卷保留着这一出处。

• The current imprint reads Hoboken, New Jersey, Wiley, 2023 onwards, which dates the Wiley imprint from that year.现行出版项写的是新泽西州霍博肯的 Wiley，起于 2023 年，说明这一年起刊物已由 Wiley 出版。

• Articles keep the DOI prefix 10.1155 that Hindawi assigned, so citations to the Hindawi-era volumes still resolve under the original prefix.文章保留 Hindawi 时代分配的 DOI 前缀 10.1155，指向 Hindawi 时期各卷的引文仍按原前缀解析。

• Wiley lists the title under journal number 7507 and places it in the Forward Series, its programme for open access titles.Wiley 用刊号 7507 列出这份刊物，并把它归入 Forward Series，即该社的开放获取期刊系列。

• Volume numbers follow the calendar, so the 2026 volume is numbered 2026 and the year of publication is written into the citation itself.卷号跟着年份走，2026 年即第 2026 卷，出版年份直接写进引文。

• One issue per volume has been the rule since 2024, and articles appear as they become ready instead of waiting for a collected number.2024 年起每卷只出一期，文章就绪即上线，不必等凑齐一期。

• The pair of ISSNs, 2090-1852 in print and 2090-1860 online, survived the change of publisher without alteration to either number.两个 ISSN 分别是印本 2090-1852 与网络版 2090-1860，更换出版方之后两个号都原样保留。

• Open access has been the only route since the 2010 volume, and the 2025 Journal Citation Reports put the gold share at 100 per cent.自 2010 卷起开放获取就是唯一路径，2025 年期刊引证报告给出的金色开放获取比例为 100%。

• Articles carry a CC BY licence by default, with CC BY-NC or CC BY-NC-ND available where a funder requires one of the two.文章默认采用 CC BY 许可，资助方另有要求时可改用 CC BY-NC 或 CC BY-NC-ND。

• No submission fee and no page charge are levied, and the article processing charge is the only cost the guidelines describe in connection with publication.不收投稿费与版面费，投稿指南里与发表相关的费用只有文章处理费一项。

• The 2025 Journal Impact Factor is 2.4, the five-year figure is 2.6, CiteScore is 4.6 and the Journal Citation Indicator is 0.52.2025 年期刊影响因子为 2.4，五年影响因子为 2.6，CiteScore 为 4.6，期刊引证指标为 0.52。

• The impact factor stood at 1.7 for 2023, rose to 2.8 for 2024 and settled at 2.4 for 2025.影响因子 2023 年为 1.7，2024 年升到 2.8，2025 年落在 2.4。

• Output stays small at about five articles a year, with 577 citations recorded and a cited half-life of 10.3 years, all taken from the 2025 Journal Citation Reports.年发文量维持在 5 篇上下，记录到的总被引为 577 次，被引半衰期 10.3 年，这些数字取自 2025 年期刊引证报告。

• The title sits in the Emerging Sources Citation Index, in a single JCR category, NEUROSCIENCES, at 225 of 330 journals and in the third quartile.刊物收录于 Emerging Sources Citation Index，在 JCR 中只有 NEUROSCIENCES 一个类目，330 种里排第 225 位，属第三四分位。

• Abstracting and indexing reach PubMed and PubMed Central as well as Scopus, Embase, DOAJ, CINAHL and J-Gate, a span wider than the citation index on its own.摘要与索引覆盖 PubMed 与 PubMed Central，还包括 Scopus、Embase、DOAJ、CINAHL 以及 J-Gate，覆盖面比单一的引文索引更宽。

Editors

• No editor-in-chief is named on the board page. Ankit Dhoundiyal, an associate editor at Wiley in India, is the editorial contact and coordinates the office.编委页没有列出主编。Wiley 在印度的副编辑（Ankit Dhoundiyal）是编辑部联系人，负责统筹编辑事务。

• Twelve academic editors handle manuscripts, and between them they sit in clinical departments and neuroscience institutes across five countries.12 位学术编辑处理稿件，分别任职于 5 个国家的临床科室与神经科学研究机构。

• All twelve are university or hospital appointees, and the Wiley side of the operation is represented by the office contact alone.12 人全部由高校或医院任职者担任，Wiley 一方只由编辑部联系人出面。

• Murat Atagun works at Çanakkale Onsekiz Mart University in Turkey, and Muaz Belviranli holds a post at Selçuk University in the same country.（Murat Atagun）在土耳其的 Çanakkale Onsekiz Mart University 任职，（Muaz Belviranli）在同国的 Selçuk University 任教。

• Yunus Emre Kundakçı completes a Turkish group of three, at Afyonkarahisar Health Sciences University in the west of the country.土耳其的第三位是（Yunus Emre Kundakçı），在土耳其西部的 Afyonkarahisar Health Sciences University。

• Italy holds three seats, filled by Stefano Barlati at the University of Brescia, Rita Chiaramonte at the University of Catania and Vincenzo Di Lazzaro at Campus Bio-Medico University.意大利占 3 席，分别是 University of Brescia 的（Stefano Barlati）、University of Catania 的（Rita Chiaramonte）与 Campus Bio-Medico University 的（Vincenzo Di Lazzaro）。

• Four editors work in the United States. Jeff Bronstein is at UCLA, and Fady T. Charbel at the University of Illinois at Chicago.美国有 4 位编辑。（Jeff Bronstein）在 UCLA，（Fady T. Charbel）在 University of Illinois at Chicago。

• Tahmineh Mokhtari is based at UC Davis and Mohd Salman at Indiana University, which accounts for the other two American seats.（Tahmineh Mokhtari）在 UC Davis，（Mohd Salman）在 Indiana University，美国其余两席由此补齐。

• Mohammed E. Choudhury works at Ehime University in Japan and Hajime Hirase at the University of Copenhagen in Denmark, the last two places on the list.名单上最后两席由日本 Ehime University 的（Mohammed E. Choudhury）与丹麦 University of Copenhagen 的（Hajime Hirase）担任。

• Review is single anonymised, so referees read a manuscript without author names while authors never learn which colleagues judged the paper.评审采用单盲方式，审稿人读到的稿件隐去作者姓名，作者始终不知道是哪几位同行审的稿。

• Two external reports are the minimum the guidelines ask for on any manuscript that clears the editorial check.通过编辑初筛的稿件，投稿指南要求至少有两份外部审稿意见。

• The median time from submission to first decision is 57 days, and 16 per cent of submissions end in acceptance.从投稿到首次决定的中位时间为 57 天，接收率为 16%。

• A corresponding author has to hold an ORCID identifier before a manuscript can enter the submission system at all.通讯作者须先持有 ORCID 标识，稿件才能进入投稿系统。

• Clinical trials must be registered publicly under ICMJE rules ahead of submission, and the guidelines state that requirement near the top.临床试验须在投稿前按 ICMJE 规则完成公共注册，投稿指南把这一条写在靠前的位置。

• Preprints are allowed, but a single author may have no more than three manuscripts under review with the journal at any one time.预印本允许先行发布，但同一作者同时在该刊评审中的稿件最多 3 篇。